CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 23 enrolled
Drug / intervention
voriconazoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00721578
NCT00721578N/ACompleted
CompareCT.gov

An Observational Study Of Patients Receiving Therapy For Systemic Fungal Infections

Pfizer·observational·Posted Jul 24, 2008·Updated Jan 10, 2011

In Brief

An observational study evaluating voriconazole for Systemic Fungal Infections. Completed, enrolled 23 participants across 3 sites.

Detailed Summary

To collect and summarize information on the diagnosis, management, and clinical and mycological outcomes of patients with systemic fungal infections in order to better understand the effectiveness of antifungals in the treatment of Systemic Fungal Infections (SFI) in India.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Fungal Infections
CountriesIndia
Collaborators--

Timeline

N/ACompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 24, 2008
Enrollment StartApr 1, 2009
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.9 years ago

Interventions

voriconazoledrug

Patients must have received (in the Intensive Care Unit \[ICU\] at study entry) at least 1 day therapy with systemic antifungal agent for treatment of a proven or suspected fungal infection. The decision regarding choice of antifungal agent would lie with the treating physician and will necessarily precede and be independent of the decision to enroll a patient into the study.